Cargando…

Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro

Bufalin (buf) has poor solubility in aqueous solution, poor tumor targeting, and many non-specific toxic and side effects. The advantages of high-molecular-weight polymer conjugates are that they can improve the water solubility of buf, prolong plasma half-life, and reduce non-specific toxicity. A n...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jiankun, Lin, Shanmeng, Hu, Hao, Xing, Qi, Geng, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653589/
https://www.ncbi.nlm.nih.gov/pubmed/36365509
http://dx.doi.org/10.3390/polym14214515
_version_ 1784828717270302720
author Xu, Jiankun
Lin, Shanmeng
Hu, Hao
Xing, Qi
Geng, Jin
author_facet Xu, Jiankun
Lin, Shanmeng
Hu, Hao
Xing, Qi
Geng, Jin
author_sort Xu, Jiankun
collection PubMed
description Bufalin (buf) has poor solubility in aqueous solution, poor tumor targeting, and many non-specific toxic and side effects. The advantages of high-molecular-weight polymer conjugates are that they can improve the water solubility of buf, prolong plasma half-life, and reduce non-specific toxicity. A novel water-soluble polymer–drug conjugate with buf and fluorescein pendants was prepared by the combination of reversible addition-fragmentation transfer (RAFT) polymerization and click chemistry. Its anticancer performance and cellular uptake behavior against liver cancer were investigated in vitro. The polymer–buf conjugates exhibit controlled release and tumor-targeting capabilities, showing promise for clinical applications.
format Online
Article
Text
id pubmed-9653589
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96535892022-11-15 Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro Xu, Jiankun Lin, Shanmeng Hu, Hao Xing, Qi Geng, Jin Polymers (Basel) Article Bufalin (buf) has poor solubility in aqueous solution, poor tumor targeting, and many non-specific toxic and side effects. The advantages of high-molecular-weight polymer conjugates are that they can improve the water solubility of buf, prolong plasma half-life, and reduce non-specific toxicity. A novel water-soluble polymer–drug conjugate with buf and fluorescein pendants was prepared by the combination of reversible addition-fragmentation transfer (RAFT) polymerization and click chemistry. Its anticancer performance and cellular uptake behavior against liver cancer were investigated in vitro. The polymer–buf conjugates exhibit controlled release and tumor-targeting capabilities, showing promise for clinical applications. MDPI 2022-10-25 /pmc/articles/PMC9653589/ /pubmed/36365509 http://dx.doi.org/10.3390/polym14214515 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xu, Jiankun
Lin, Shanmeng
Hu, Hao
Xing, Qi
Geng, Jin
Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro
title Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro
title_full Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro
title_fullStr Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro
title_full_unstemmed Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro
title_short Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro
title_sort tumor-targeting polymer–drug conjugate for liver cancer treatment in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653589/
https://www.ncbi.nlm.nih.gov/pubmed/36365509
http://dx.doi.org/10.3390/polym14214515
work_keys_str_mv AT xujiankun tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro
AT linshanmeng tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro
AT huhao tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro
AT xingqi tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro
AT gengjin tumortargetingpolymerdrugconjugateforlivercancertreatmentinvitro